Who are CHF 1535 50/6µg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): mometasone furoate and formoterol, FF, Beclometasone/Formoterol, Fluticasone Furoate/GW642444, CHF 1535 100/6 NEXT DPI® 2 months, Beclomethasone Dipropionate/Formoterol Fumarate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chf-1535-50-6-g.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CHF 1535 50/6µg — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CHF 1535 50/6µg (CHF 1535 50/6µg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination. Area: Respiratory/Pulmonology.

phase 3 Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination Glucocorticoid receptor (GR); Beta-2 adrenergic receptor (β2AR) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

CHF 1535 50/6µg (CHF 1535 50/6µg) — Chiesi Farmaceutici S.p.A.. CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CHF 1535 50/6µg TARGET	CHF 1535 50/6µg	Chiesi Farmaceutici S.p.A.	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor (GR); Beta-2 adrenergic receptor (β2AR)
mometasone furoate and formoterol	mometasone furoate and formoterol	Sanofi	marketed	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor (mometasone); beta-2 adrenergic receptor (formoterol)
FF	FF	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor; beta-2 adrenergic receptor
Beclometasone/Formoterol	Beclometasone/Formoterol	Chiesi Farmaceutici S.p.A.	marketed	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor (beclometasone); beta-2 adrenergic receptor (formoterol)
Fluticasone Furoate/GW642444	Fluticasone Furoate/GW642444	GlaxoSmithKline	phase 3	Long-acting inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor (fluticasone furoate); beta-2 adrenergic receptor (GW642444/vilanterol)
CHF 1535 100/6 NEXT DPI® 2 months	CHF 1535 100/6 NEXT DPI® 2 months	Chiesi Farmaceutici S.p.A.	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor; beta-2 adrenergic receptor
Beclomethasone Dipropionate/Formoterol Fumarate	Beclomethasone Dipropionate/Formoterol Fumarate	Alfredo Antonio Chetta	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination class)

Chiesi Farmaceutici S.p.A. · 6 drugs in this class
Alfredo Antonio Chetta · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Sanofi · 1 drug in this class
SkyePharma AG · 1 drug in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CHF 1535 50/6µg — Competitive Intelligence Brief. https://druglandscape.com/ci/chf-1535-50-6-g. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab